Precision BioSciences Inc (NAS:DTIL)
$ 7.29 0.18 (2.53%) Market Cap: 55.92 Mil Enterprise Value: -14.97 Mil PE Ratio: 121.50 PB Ratio: 0.84 GF Score: 59/100

Precision BioSciences Inc at HC Wainwright Cell Therapy Virtual Conference Transcript

Feb 28, 2023 / 07:00PM GMT
Release Date Price: $33.6 (+1.82%)
Patrick Trucchio
H.C. Wainwright & Co., LLC - Analyst

Good afternoon, everyone, and welcome back to H.C. Wainwright's Cell Therapy Virtual Conference. My name is Patrick Trucchio. I'm a senior biotech analyst at H.C. Wainwright. And it's my pleasure to introduce our next speakers: Michael Amoroso, CEO; Derek Jantz, CSO; and Alan List, CMO of Precision BioSciences, a clinical-stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies.

And with that, I'll hand over the presentation to Michael for the introduction.

Michael Amoroso
Precision BioSciences, Inc. - President & CEO

Thank you, Patrick, and thank you to the Wainwright team for having us. Excited to be with everyone today. Before I hand it over to Dr. List in the moment here, I'll take you through some updates on our allogeneic CAR T programs. Wanted to give a brief background of Precision BioSciences. We say we're a small but mighty group out of Durham. A little less than 200 folks in the Durham, North Carolina area.

We are,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot